Dapagliflozin

Specifications

461432-26-8CAS Number

639-683-0EC Number

(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triolIUPAC Name

C21H25ClO6Chemical Formula

408.9 g/molMolecular Weight

Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; dapagliflozine; Dapagliflozina; 1ULL0QJ8UC; LYN-045; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; CHEBI:85078; DTXSID20905104; DAPAGLIFLOZIN COMPONENT QTERNMET; QTERNMET XR COMPONENT DAPAGLIFLOZIN; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; BMS512148; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; dapagliflozinum; (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol; RefChem:54930; A10BK01; DTXCID101334207; 639-683-0; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; Dagagflozin; MFCD13182359; CHEMBL429910; Dapagliflozin [USAN:INN]; Forxiga (TN); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; Dapagliflozin [USAN]; C21H25ClO6; UNII-1ULL0QJ8UC; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; BMS 512148; Dapagliflozin; Farxiga; DAPAGLIFLOZIN?; C-aryl glucoside, 6; Dapagliflozin (Standard); DAPAGLIFLOZIN [MI]; DAPAGLIFLOZIN [INN]; DAPAGLIFLOZIN [VANDF]; SCHEMBL157820; DAPAGLIFLOZIN [WHO-DD]; GTPL4594; orb1305553; orb3012985; orb3141347; BR1019 component Dapagliflozin; Dapagliflozin (JAN/USAN/INN); SCHEMBL29364603; BDBM20880; EX-A005; Dapagliflozin - Bio-X trade mark; JVHXJTBJCFBINQ-ADAARDCZSA-N; GLXC-90177; DAPAGLIFLOZIN [ORANGE BOOK]; MSK11068; EBC-11348; HY-10450R; s1548; QTERNMET COMPONENT DAPAGLIFOZIN; AKOS005145763; BL-0052; BMS5121458; CCG-229917; CS-0781; DB06292; EX-7214; MD20795; 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; NCGC00250402-02; NCGC00250402-09; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; AC-24699; BD164346; HY-10450; SY028092; 5168A; NS00099173; C22193; D08897; EN300-7407160; D019601; F794039; Q409898; BRD-K58160573-001-01-3; BRD-K58160573-001-04-7; BRD-K58160573-001-05-4; Z2235801883; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; (1S)-1,5-Anhydro-1-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; LE6Synonyms